Lessons from the BEAT trial: implications for inhaled treprostinil from a double-blind, randomized trial
Abstract Background Combination therapy is recommended for pulmonary arterial hypertension (PAH), part of which generally includes prostanoids, which affect both the vascular tone and vessel remodeling seen in PAH. This study tested whether a dual prostacyclin treatment strategy (oral esuberaprost + inhaled treprostinil and oral background PAH therapies) would provide additional clinical benefit. Methods 271 World Health Organization functional class (FC) III/IV patients with PAH received placebo or 28.4 µg oral esuberaprost 4 times daily, in addition to newly initiated or ongoing inhaled treprostinil and background therapies. Results There was no difference between treatment groups in time to clinical worsening (primary endpoint); 49 (36.0%) patients on esuberaprost and 51 (37.8%) on placebo had a clinical worsening event. No favorable esuberaprost treatment effects were observed for the secondary or exploratory endpoints (6-minute walk distance [6MWD], Borg dyspnea score, and N-terminal pro-brain natriuretic peptide [NT-proBNP]). There were 21 all-cause deaths attributable to clinical worsening (esuberaprost: 8 [5.9%]; placebo: 13 [9.6%]). Post hoc exploratory analyses to investigate the effect of inhaled treprostinil on treprostinil-naïve patients ( n = 151) found that the addition of inhaled treprostinil was associated with improvements in multiple components of risk status, NT-proBNP, and 6MWD from screening through week 52, irrespective of background therapy. Notably, similar improvements were observed in patients on dual background therapy. Conclusion While the study did not meet its primary endpoint, the post hoc findings were consistent with current guideline recommendations to use multidimensional risk assessment when evaluating treatment response in PAH. Trial registration Beraprost-314d Added-on to Tyvaso ® (BEAT) NCT01908699; Registered 2013-07-26 https://clinicaltrials.gov/study/NCT01908699.
Authors
- David C. Ishizawar
- Jeffrey S. Sager
- Aaron B. Waxman (ORCID: https://orcid.org/0000-0001-7797-0361)
- Robert C. Bourge (ORCID: https://orcid.org/0000-0001-9035-4133)
- Mordechai Reuven Kramer (ORCID: https://orcid.org/0000-0003-2376-2393)
- Ronald J. Oudiz (ORCID: https://orcid.org/0000-0002-0291-3554)
- Mary Lou Tomson
- Meredith J. Broderick (ORCID: https://orcid.org/0000-0002-1871-1615)
- Rajan Saggar (ORCID: https://orcid.org/0000-0002-5536-5934)
- Boris I. Medarov (ORCID: https://orcid.org/0000-0002-8132-7122)
- H. James Ford
- Shelly Shapiro
- Prakash Sista (ORCID: https://orcid.org/0000-0002-4156-3374)
- M. I. Lorber
- Aimee Smart
- Jordan Shin
- F Rahaghi (ORCID: https://orcid.org/0000-0003-0803-4005)
- Sonja Bartolome
- Robert Naeije
- Michael DiMarino
- Y Rao
Institutions
- University of North Carolina at Chapel Hill (US)
- Brigham and Women's Hospital (US)
- Université Libre de Bruxelles (BE)
- University of California, Los Angeles (US)
- The Lundquist Institute (US)
- Medical College of Wisconsin (US)
- Rabin Medical Center (IL)
- UCLA Medical Center (US)
- Rex Hospital (US)
- University of Alabama at Birmingham (US)
- Los Angeles Medical Center (US)
- Los Angeles Biomedical Research Institute (US)
- United Therapeutics (United States) (US)
- Cottage Health (US)
- Southwestern Medical Center (US)
- Albany Medical College (US)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- BMC Pulmonary Medicine
- Published
- 2026-11-17
- DOI
- https://doi.org/10.1186/s12890-026-04973-x
- Primary Topic
- Pulmonary Hypertension Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pfizer
- United Therapeutics Corporation
- Insmed
- AOP Orphan